Literature DB >> 14714916

A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus.

M Bodani1, M D Kopelman.   

Abstract

A brief description of psychosis in the general psychiatric setting and its treatment using antipsychotic agents including 'atypical' drugs. A review of the prevalence of neuropsychiatric syndromes in lupus (using The American College of Rheumatology standardized definitions) from recent studies showing wide variation in reported rates. Underlying pathophysiologic mechanisms postulated for neuropsychiatric manifestations of lupus are reviewed with implications for treatment. The use and success of intravenous pulsed cyclophosphamide (singly and in combination with methylprednisiolone) for severe neuropsychiatric psychosis is reviewed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14714916     DOI: 10.1191/0961203303lu507oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Effectiveness of olanzapine for systemic lupus erythematosus-related psychosis.

Authors:  Joel P Pinto; Silvio Luiz Morais; Jaime E C Hallak; Serdar M Dursun
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  MR imaging findings suggestive of posterior reversible encephalopathy syndrome in adolescents with systemic lupus erythematosus.

Authors:  Eyal Muscal; Elfrides Traipe; Marietta M de Guzman; Barry L Myones; Robin L Brey; Jill V Hunter
Journal:  Pediatr Radiol       Date:  2010-01-30

Review 3.  Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus.

Authors:  Virginia Fernandes Moça Trevisani; Aldemar A Castro; João Ferreira Neves Neto; Alvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

4.  Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre.

Authors:  Esha Abrol; Ester Coutinho; Michael Chou; Melanie Hart; Angela Vincent; Robert Howard; Michael S Zandi; David Isenberg
Journal:  Rheumatology (Oxford)       Date:  2021-12-01       Impact factor: 7.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.